REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease

Inclusion criteria

• Diagnosed with CAD and PCI was successfully performed.
• Presence of non-target lesions near the target lesion (more than 5mm proximal or distal), with stenosis of 20% to 50% and identifiable anatomical markers (e.g., branches, calcifications, stent edges).
• 18 to 75 years old.
• Written informed consent.

Exclusion criteria

• Known autoimmune diseases, or taking immunosuppressive drugs for a long time before onset.
• Known familial hypercholesterolemia.
• Critical conditions (e.g., cardiogenic shock, acute heart failure).
• Severe renal insufficiency (eGFR < 30 mL /(min·1.73m2)), or severe hepatic insufficiency (ALT or AST≥3 times the upper limit of normal).
• Severe underlying diseases (such as end-stage malignancies), life expectancy < 1 year.
• Allergic to lipid-lowering medications.
• Pregnant, or trying to become pregnant, and breastfeeding women.
• Other conditions deemed unsuitable for inclusion by the researcher.